ORMP
ORAMED PHARMACEUTICALS INC.
NASDAQ · Healthcare · Biotechnology · US
$4.74
+1.50%0
Insider buys (3m)
2
Insider sells (3m)
-$942.2K
Net value (3m)
+15.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Hexter Joshua · officer: COO & CBO | M-Exempt | 50,000 | $3.69 |
| Jul 2, 2026 | Hexter Joshua · officer: COO & CBO | Sale | 137,000 | $4.46 |
| Jul 2, 2026 | Gabay Avraham · officer: Chief Financial Officer | Sale | 73,360 | $4.51 |
| Mar 31, 2026 | KIDRON NADAV · director, officer: President and CEO | F-InKind | 44,818 | $3.31 |
| Mar 31, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | F-InKind | 435,084 | $3.31 |
| Mar 18, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | A-Award | 119,558 | $0.00 |
| Mar 18, 2026 | Gabay Avraham · officer: Chief Financial Officer | A-Award | 95,889 | $0.00 |
| Mar 18, 2026 | Hexter Joshua · officer: COO & CBO | A-Award | 95,889 | $0.00 |
| Mar 18, 2026 | KIDRON NADAV · director, officer: President and CEO | A-Award | 167,005 | $0.00 |
| Jan 29, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | M-Exempt | 19,000 | $0.00 |
| Jan 29, 2026 | Gabay Avraham · officer: Chief Financial Officer | M-Exempt | 19,000 | $0.00 |
| Jan 29, 2026 | KIDRON NADAV · director, officer: President and CEO | M-Exempt | 109,000 | $0.00 |
| Jan 29, 2026 | Hexter Joshua · officer: COO & CBO | M-Exempt | 19,000 | $0.00 |
| Jan 5, 2026 | Reznick Yehuda · director | A-Award | 30,000 | $0.01 |
| Jan 5, 2026 | KIDRON NADAV · director, officer: President and CEO | A-Award | 327,000 | $0.00 |
| Jan 5, 2026 | KIDRON NADAV · director, officer: President and CEO | A-Award | 232,640 | $0.00 |
| Jan 5, 2026 | KIDRON NADAV · director, officer: President and CEO | A-Award | 109,000 | $0.00 |
| Jan 5, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | A-Award | 115,000 | $0.00 |
| Jan 5, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | A-Award | 121,331 | $0.00 |
| Jan 5, 2026 | Kidron Miriam · director, officer: Chief Scientific Officer | A-Award | 19,000 | $0.00 |
| Jan 5, 2026 | Hexter Joshua · officer: COO & CBO | A-Award | 115,000 | $0.00 |
| Jan 5, 2026 | Hexter Joshua · officer: COO & CBO | A-Award | 97,328 | $0.00 |
| Jan 5, 2026 | Hexter Joshua · officer: COO & CBO | A-Award | 19,000 | $0.00 |
| Jan 5, 2026 | Shapiro Benjamin · director | A-Award | 3,500 | $0.00 |
| Jan 5, 2026 | Shapiro Benjamin · director | A-Award | 30,000 | $0.01 |
| Jan 5, 2026 | Mayer Arie · director | A-Award | 4,900 | $0.00 |
| Jan 5, 2026 | Mayer Arie · director | A-Award | 30,000 | $0.01 |
| Jan 5, 2026 | Reznick Yehuda · director | A-Award | 6,250 | $0.00 |
| Jan 2, 2026 | Aghion Daniel · director | A-Award | 6,250 | $0.00 |
| Jan 2, 2026 | Aghion Daniel · director | A-Award | 30,000 | $0.01 |
Institutional positioning
13F filings over the trailing two quarters
New 45Increased 40Reduced 35Sold out 8
| Filer | Action | Shares | Filed |
|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | Increased | 3,810,540 | Aug 19, 2026 |
| BML CAPITAL MANAGEMENT, LLC | Unchanged | 3,167,231 | May 6, 2026 |
| Aquamarine Financial (Cayman) Ltd | Increased | 2,512,175 | Aug 12, 2026 |
| Aquamarine Financial (Cayman) Ltd | Increased | 2,112,312 | May 15, 2026 |
| Gem Investment Advisors, LLC | Increased | 1,998,802 | Aug 11, 2026 |
| MERCER GLOBAL ADVISORS INC /ADV | New Position | 1,910,540 | May 15, 2026 |
| GEM INVESTMENT ADVISORS, LLC | Reduced | 1,640,069 | May 15, 2026 |
| BlackRock, Inc. | Increased | 1,608,111 | Aug 7, 2026 |
| MURCHINSON LTD. | Reduced | 1,315,294 | May 15, 2026 |
| Murchinson Ltd. | Reduced | 1,290,294 | Aug 14, 2026 |
| BML Capital Management, LLC | Reduced | 866,269 | Aug 7, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | Reduced | 600,716 | May 15, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | Reduced | 578,638 | Aug 14, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 500,690 | Aug 12, 2026 |
| MARSHALL WACE, LLP | Increased | 259,611 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 2, 2026